In this study, we find that Hsp90α promotes lipid accumulation by increasing FASN protein stability and mRNA transcription, and can be alleviated by Hsp90 inhibitors via LXRα-SREBP1 axis, which reveals a mechanism for potential Hsp90-targeted therapy on lipid metabolism in HCC. The gene discussed is FASN; the disease is hepatocellular carcinoma.